| __timestamp | CRISPR Therapeutics AG | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 17763000 |
| Thursday, January 1, 2015 | 13403000 | 22180000 |
| Friday, January 1, 2016 | 31056000 | 37257000 |
| Sunday, January 1, 2017 | 35845000 | 27367000 |
| Monday, January 1, 2018 | 48294000 | 64770000 |
| Tuesday, January 1, 2019 | 63488000 | 74986000 |
| Wednesday, January 1, 2020 | 88208000 | 79256000 |
| Friday, January 1, 2021 | 102802000 | 100156000 |
| Saturday, January 1, 2022 | 102464000 | 131408000 |
| Sunday, January 1, 2023 | 76162000 | 152946000 |
| Monday, January 1, 2024 | 72977000 |
Unlocking the unknown
In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: CRISPR Therapeutics AG and Dynavax Technologies Corporation, from 2014 to 2023.
CRISPR Therapeutics AG, a leader in gene-editing technology, saw its SG&A expenses grow by approximately 1,400% over the decade, peaking in 2021. Meanwhile, Dynavax Technologies, known for its innovative vaccine solutions, experienced a 760% increase, with a notable surge in 2023.
Despite CRISPR's early lead, Dynavax's expenses surpassed CRISPR's by 2023, reflecting its aggressive market expansion. This trend highlights the dynamic nature of biotech financials, where strategic investments in administration and sales can significantly impact a company's growth trajectory.
Bristol-Myers Squibb Company or Dynavax Technologies Corporation: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Biogen Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: SG&A Expense Trends
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or CRISPR Therapeutics AG
Alpine Immune Sciences, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.
R&D Spending Showdown: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Wave Life Sciences Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Galapagos NV
Dynavax Technologies Corporation vs MiMedx Group, Inc.: SG&A Expense Trends